Spima TherapeuticsPartnershipSpima Therapeutics starts with global licence agreementLatest NewsSPIMA Therapeutics SA lauches with €1m investment by SATT AxLR, which has licenced the company’s lead programme, SP-001 Read more 1 October 2024 https://european-biotechnology.com/wp-content/uploads/2024/10/SPIMA-e1727778052587.png 319 566 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2024-10-01 12:21:532024-10-03 08:44:09Spima Therapeutics starts with global licence agreement